Prognostic and Predictive Factors for Renal Cell Carcinoma

Overview

Journal Target Oncol

Specialty Oncology

Date 2018 Mar 24

PMID 29569164

Citations 4

Authors

Cristina Suarez

Marc Campayo

Roma Bastus

Sergi Castillo

Olatz Etxanitz

Marta Guix

Nuria Sala

Enrique Gallardo

Affiliations

Soon will be listed here.

Abstract

Metastatic renal cell carcinoma (mRCC) is an incurable malignancy, characterized by its resistance to traditional chemotherapy, radiation, and hormonal therapy. Treatment perspectives and prognosis of patients with mRCC have been significantly improved by advances in the understanding of its molecular pathogenesis, which have led to the development of targeted therapeutics. Different molecular factors derived from the tumor or the host detected in both tissue or serum could be predictive of therapeutic benefit. Some of them suggest a rational selection of patients to be treated with certain therapies, though none have been validated for routine use. This article provides an overview of both clinical and molecular factors associated with predictive or prognostic value in mRCC and emphasizes that both should be considered in parallel to provide the most appropriate, individualized treatment and achieve the best outcomes in clinical practice.

Citing Articles

The prognostic role of perirenal fat tissue in non-metastatic renal cell carcinoma.

Besler M, Olcucuoglu E, Olcucuoglu E Jpn J Radiol. 2024; 42(11):1262-1269.

PMID: 38856877 DOI: 10.1007/s11604-024-01609-0.

A three miRNAs panel in paraffin tissue serves as tool for predicting prognosis of renal cell carcinoma.

Chen W, Wang W, Zhao Z, Wen Z, Li Y, Ge Z Front Oncol. 2024; 14:1391844.

PMID: 38720802 PMC: 11076680. DOI: 10.3389/fonc.2024.1391844.

Machine learning algorithms being an auxiliary tool to predict the overall survival of patients with renal cell carcinoma using the SEER database.

Jiang W, Chen Z, Chen C, Wang L, Han T, Wen L Transl Androl Urol. 2024; 13(1):53-63.

PMID: 38404544 PMC: 10891382. DOI: 10.21037/tau-23-319.

Prognostic factors in renal cell carcinoma: A single‑center study.

Ali R, Muhealdeen D, Fakhralddin S, Bapir R, Tahir S, Rashid R Mol Clin Oncol. 2023; 19(3):66.

PMID: 37614366 PMC: 10442722. DOI: 10.3892/mco.2023.2662.

References

Gilbert S, Murphy A, Katz A, Goluboff E, Sawczuk I, Olsson C . Reevaluation of TNM staging of renal cortical tumors: recurrence and survival for T1N0M0 and T3aN0M0 tumors are equivalent. Urology. 2006; 68(2):287-91. DOI: 10.1016/j.urology.2006.02.012. View

Tomita Y, Uemura H, Fujimoto H, Kanayama H, Shinohara N, Nakazawa H . Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. Eur J Cancer. 2011; 47(17):2592-602. DOI: 10.1016/j.ejca.2011.07.014. View

Kim H, Belldegrun A, Freitas D, Bui M, Han K, Dorey F . Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J Urol. 2003; 170(5):1742-6. DOI: 10.1097/01.ju.0000092764.81308.6a. View

Zhu X, Wu S, Dahut W, Parikh C . Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007; 49(2):186-93. DOI: 10.1053/j.ajkd.2006.11.039. View

Al-Marrawi M, Rini B, Harshman L, Bjarnason G, Wood L, Vaishampayan U . The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Target Oncol. 2013; 8(3):203-209. PMC: 4144038. DOI: 10.1007/s11523-012-0252-7. View

Choueiri T, Regan M, Rosenberg J, Oh W, Clement J, Amato A . Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int. 2010; 106(6):772-8. DOI: 10.1111/j.1464-410X.2010.09218.x. View

Klatte T, Streubel B, Wrba F, Remzi M, Krammer B, de Martino M . Renal cell carcinoma associated with transcription factor E3 expression and Xp11.2 translocation: incidence, characteristics, and prognosis. Am J Clin Pathol. 2012; 137(5):761-8. DOI: 10.1309/AJCPQ6LLFMC4OXGC. View

Heng D, Xie W, Regan M, Harshman L, Bjarnason G, Vaishampayan U . External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013; 14(2):141-8. PMC: 4144042. DOI: 10.1016/S1470-2045(12)70559-4. View

Stewart G, OMahony F, Laird A, Rashid S, Martin S, Eory L . Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer. Eur Urol. 2014; 66(5):956-63. PMC: 4410300. DOI: 10.1016/j.eururo.2014.04.007. View

10.

Choueiri T, Fay A, Gray K, Callea M, Ho T, Albiges L . PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol. 2014; 25(11):2178-2184. PMC: 4288138. DOI: 10.1093/annonc/mdu445. View

11.

Thompson R, Kuntz S, Leibovich B, Dong H, Lohse C, Webster W . Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006; 66(7):3381-5. DOI: 10.1158/0008-5472.CAN-05-4303. View

12.

Frigola X, Inman B, Lohse C, Krco C, Cheville J, Thompson R . Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin Cancer Res. 2011; 17(7):1915-23. PMC: 3241002. DOI: 10.1158/1078-0432.CCR-10-0250. View

13.

Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M . Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2007; 5(6):379-85. DOI: 10.3816/CGC.2007.n.020. View

14.

Choueiri T, Fay A, Gagnon R, Lin Y, Bahamon B, Brown V . The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. Clin Cancer Res. 2013; 19(18):5218-26. PMC: 4522695. DOI: 10.1158/1078-0432.CCR-13-0491. View

15.

Garcia-Donas J, Leandro-Garcia L, Gonzalez Del Alba A, Morente M, Alemany I, Esteban E . Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma. Ann Oncol. 2013; 24(9):2409-14. DOI: 10.1093/annonc/mdt219. View

16.

Choueiri T, Figueroa D, Fay A, Signoretti S, Liu Y, Gagnon R . Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. Clin Cancer Res. 2014; 21(5):1071-7. DOI: 10.1158/1078-0432.CCR-14-1993. View

17.

Heng D, Xie W, Regan M, Warren M, Golshayan A, Sahi C . Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009; 27(34):5794-9. DOI: 10.1200/JCO.2008.21.4809. View

18.

Smith A, Lieber M, Shah S . Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR Am J Roentgenol. 2009; 194(1):157-65. DOI: 10.2214/AJR.09.2941. View

19.

Pena C, Lathia C, Shan M, Escudier B, Bukowski R . Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res. 2010; 16(19):4853-63. DOI: 10.1158/1078-0432.CCR-09-3343. View

20.

Kontovinis L, T Papazisis K, Touplikioti P, Andreadis C, Mouratidou D, Kortsaris A . Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. BMC Cancer. 2009; 9:82. PMC: 2662874. DOI: 10.1186/1471-2407-9-82. View